A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
NCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05923008 Brief Summary This is a phase 1/2 multicenter, open-label, first-in-human…
Read more arrow_forwardNCT 05763004 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 06625593 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 06914128 Brief Summary The study treatment, BAY 3713372, is under development…
Read more arrow_forwardNCT 05858164 Brief Summary Researchers are looking for a better way…
Read more arrow_forwardNCT 05999994 Brief Summary The main purpose of the master is to…
Read more arrow_forwardNCT 06170190 Brief Summary This is a multicentre, open-label, first-in-human, phase 1/2…
Read more arrow_forwardNCT 04801095 Brief Summary This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics,…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forward